Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Chinese Patients With Type 2 Diabetes Mellitus

Trial Profile

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Chinese Patients With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Dec 2018 Planned End Date changed from 29 Jan 2020 to 27 Apr 2020.
    • 18 Dec 2018 Planned primary completion date changed from 29 Jan 2020 to 27 Apr 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top